PALISADE BIO INC (PALI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PALI • US6963894026

1.49 USD
-0.12 (-7.45%)
At close: Jan 30, 2026
1.5395 USD
+0.05 (+3.32%)
After Hours: 1/30/2026, 8:12:12 PM
Fundamental Rating

2

Overall PALI gets a fundamental rating of 2 out of 10. We evaluated PALI against 525 industry peers in the Biotechnology industry. PALI has a great financial health rating, but its profitability evaluates not so good. PALI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • PALI had negative earnings in the past year.
  • In the past year PALI has reported a negative cash flow from operations.
  • PALI had negative earnings in each of the past 5 years.
  • PALI had a negative operating cash flow in each of the past 5 years.
PALI Yearly Net Income VS EBIT VS OCF VS FCFPALI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • PALI's Return On Assets of -132.70% is on the low side compared to the rest of the industry. PALI is outperformed by 81.52% of its industry peers.
  • Looking at the Return On Equity, with a value of -192.71%, PALI is doing worse than 67.43% of the companies in the same industry.
Industry RankSector Rank
ROA -132.7%
ROE -192.71%
ROIC N/A
ROA(3y)-103.57%
ROA(5y)-129.62%
ROE(3y)-138.57%
ROE(5y)-188.72%
ROIC(3y)N/A
ROIC(5y)N/A
PALI Yearly ROA, ROE, ROICPALI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • PALI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PALI Yearly Profit, Operating, Gross MarginsPALI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

7

2. Health

2.1 Basic Checks

  • PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PALI has more shares outstanding
  • The number of shares outstanding for PALI has been increased compared to 5 years ago.
  • Compared to 1 year ago, PALI has an improved debt to assets ratio.
PALI Yearly Shares OutstandingPALI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
PALI Yearly Total Debt VS Total AssetsPALI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • An Altman-Z score of 18.12 indicates that PALI is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of PALI (18.12) is better than 89.90% of its industry peers.
  • There is no outstanding debt for PALI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.12
ROIC/WACCN/A
WACC8.9%
PALI Yearly LT Debt VS Equity VS FCFPALI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

  • A Current Ratio of 3.24 indicates that PALI has no problem at all paying its short term obligations.
  • PALI has a worse Current ratio (3.24) than 61.52% of its industry peers.
  • A Quick Ratio of 3.24 indicates that PALI has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.24, PALI is in line with its industry, outperforming 41.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.24
Quick Ratio 3.24
PALI Yearly Current Assets VS Current LiabilitesPALI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

1

3. Growth

3.1 Past

  • PALI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.15%, which is quite impressive.
  • PALI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)82.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.62%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.56% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y91.73%
EPS Next 2Y40.02%
EPS Next 3Y24.98%
EPS Next 5Y14.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PALI Yearly Revenue VS EstimatesPALI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
PALI Yearly EPS VS EstimatesPALI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -50K -100K -150K -200K -250K

1

4. Valuation

4.1 Price/Earnings Ratio

  • PALI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PALI Price Earnings VS Forward Price EarningsPALI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PALI Per share dataPALI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

  • PALI's earnings are expected to grow with 24.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y24.98%

0

5. Dividend

5.1 Amount

  • PALI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

PALISADE BIO INC / PALI FAQ

What is the ChartMill fundamental rating of PALISADE BIO INC (PALI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PALI.


Can you provide the valuation status for PALISADE BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to PALISADE BIO INC (PALI). This can be considered as Overvalued.


How profitable is PALISADE BIO INC (PALI) stock?

PALISADE BIO INC (PALI) has a profitability rating of 0 / 10.


How financially healthy is PALISADE BIO INC?

The financial health rating of PALISADE BIO INC (PALI) is 7 / 10.